scholarly journals Concordance with comprehensive iron assessment, hepatitis A vaccination, and hepatitis B vaccination recommendations among patients with sickle cell disease and thalassaemia receiving chronic transfusions: an analysis from the Centers for Disease Control haemoglobinopathy blood safety project

Author(s):  
Sherif M. Badawy ◽  
Amanda B. Payne ◽  
Mary M. Hulihan ◽  
Thomas D. Coates ◽  
Suvankar Majumdar ◽  
...  
Author(s):  
S. Dossim ◽  
Koffi Mawusse Guedenon ◽  
A. Chick ◽  
K. Tanga ◽  
M. Kolou ◽  
...  

Introduction: Sickle cell disease causes chronic anemia with the need for transfusions. The risk in children to get transfusions transmitted infections is high. Aims: Determine the prevalence of HBsAg and HCV antibodies in sickle cell disease children under sixteen in Lome (Togo). Study Design: It is a cross-sectional study. Place and Duration of Study: Sample: Haematology Unit of Campus University Hospital and Paediatric Unit of Sylvanus Olympio University Hospital of Lomé collected between February to May 2016. Sample processing: Campus Hospital Laboratory. Methodology: We collected blood in sickle cell disease patients in Campus and Sylvanus Olympio university hospitals at Lomé and informations about sickle cell type, transfusion, and hepatitis B vaccination. Sera were tested with Cobas e411 Roche® in the determining of hepatitis B surface antigen (HbSAg) and hepatitis C antibodies (HCVAb). Epi Info was used for statiscal analysis ®. Significant associations were found when P<0.05. Results: Total of 172 patients from Campus Hospital and 79 from Sylvanus Olympio were included. Sex ratio and SS phenotype were 0.93, 69.8% and 1.32, 64.5% respectively. HBsAg was detected in 1.7% from Campus and 7.6% in Sylvanus Olympio.  One patient from Campus carried HCVAb. Significant association between hepatitis B and sex (P=0.02) and hepatitis B and vaccination were found (P= 0.0003). Males were more infected and patients who were unvaccinated carried HBsAg. Conclusion: Vaccination against viral hepatitis and best blood donation screening are necessary to avoid these viral diseases in sickle cell disease children.


2020 ◽  
Vol 8 (4) ◽  
Author(s):  
Adefunke Olarinre Babatola ◽  
Oladele Simeon Olatunya ◽  
Ayodeji Opeyemi Faboya ◽  
Temitope Olumuyiwa Ojo ◽  
Segun Tolorunju Kayode ◽  
...  

Background: The frequent use of blood products for patients with sickle cell disease (SCD) may put them at risk of being infected with hepatitis virus infections, especially if such blood products are not properly screened. Hepatitis B and C infections (HBV and HCV, respectively) may result in cirrhosis and liver cell cancer. Objectives: This study determined the prevalence of HBV and HCV infections among pediatric patients with sickle cell disease in comparison with matched controls at the Ekiti State University Teaching Hospitals (EKSUTH), Ado-Ekiti. Methods: This was a descriptive cross-sectional study that comprised of 116 patients with SCD and their aged and sex-matched controls who were referred to the pediatric clinics at EKSUTH. The hemoglobin (Hb) genotypes of the participants were confirmed by Hb electrophoresis and high-performance liquid chromatography (HPLC), Biorad, USA Variant II, using the Beta thalassemia short program. Moreover, HBV and HCV antigens were assessed by the Enzyme-linked Immunosorbent Assay method (Kits were manufactured by Biotech Laboratories USA). Results: The mean ages of the patients with SCD and controls were 8.35 ± 4.50 and 8.92 ± 3.25 years, respectively. The seroprevalence of HBV infection among the children with sickle cell disease and controls was 1% each (P =1.00). The seroprevalence of hepatitis C virus infection was 0% among the two groups. Most (98.3%) of the patients with SCD and controls were fully vaccinated against HBV infection. The two children (100%) that were seropositive for hepatitis B were never vaccinated against HBV infection. Conclusions: The seroprevalence of HBV infection is low among patients with SCD and controls. This may be due to the protective effect of high hepatitis B vaccination rate and high quality of care among our study population.


2020 ◽  
Vol 30 (3) ◽  
pp. 226-230
Author(s):  
Suvankar Majumdar ◽  
Christopher J. Bean ◽  
Christine De Staercke ◽  
James Bost ◽  
Robert Nickel ◽  
...  

1989 ◽  
Vol 64 (4) ◽  
pp. 535-540 ◽  
Author(s):  
Q Mok ◽  
G Underhill ◽  
B Wonke ◽  
M Aldouri ◽  
M Kelsey ◽  
...  

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 4916-4916
Author(s):  
Salam Alkindi ◽  
Nada AL-Umairi ◽  
Anil Pathare

Abstract Background and Purpose: Oman is a country with an intermediate prevalence of Hepatitis B (HBV) carriers (2.8-7.1%, 20101), while the prevalence of HBV infection was 5.8% (20142). Hepatitis C (HCV) prevalence reported from Oman was 0.41% (20163). Further, a total of 2394 Human Immunodeficiency (HIV) infections were identified among Omanis (20134). Unfortunately, there are no studies on the prevalence of HIV, HBV and HCV in sickle cell disease (SCD) patients from Oman. Objectives: This study was therefore performed to estimate the prevalence of HBV, HCV and HIV among SCD patients from Oman. Methods: In a retrospective cross-sectional cohort study, medical records of all patients with SCD and sickle cell trait (SCT) patients who received blood transfusions between 2006 to 2017 were retrieved from the hospital information system. Specifically, data on HIV, HBV and HCV exposure were recorded to study the prevalence, following approval for the study from the hospital medical research and ethics committee. Results: Amongst a total of 1000 patient (491 males and 509 females), 126 (12.6%) had anti-HCV antibodies (anti-HCV) based on serology and amongst these 52(5.2%) were PCR positive. Genotype 1 was the most predominant (n=36), followed by genotype 3& 4(n=7 each) followed by genotype 2(n=2). 23 (2.3%) SCD patients showed positive serology for hepatitis B surface antigen (HbsAg) and amongst these 16 (1.6%) were PCR positive. None of the SCD patients showed positive serology for HIV. Liver Ultrasound was normal in 788 patients (78.8%), whereas, 208(20.8%) had hepatomegaly and 4(0.4%)had liver cirrhosis. Further, only 2 patients amongst the 36 patients who had died had a hepatic cause. Conclusion: This study provides comprehensive data on the prevalence of HBV and HCV infection among SCD patients and raises concerns regarding the HCV prevalence in these patients with its impact on chronic liver disease. Reassuringly, no case with HIV was observed. Disclosures No relevant conflicts of interest to declare.


2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Grace Shayo ◽  
Irene Makundi ◽  
Lucio Luzzatto

Abstract Background Tanzania ranks as the fourth country in the world with respect to the number of sickle cell disease (SCD) births; it is also endemic to the human immunodeficiency virus (HIV) and the hepatitis B virus (HBV). This study was done to determine the prevalence of HIV and HBV infections among SCD patients in Dar es Salaam, Tanzania. Methods A multicenter hospital-based descriptive cross sectional study was carried out among participants aged ≥ 16 years with a proven diagnosis of SCD. Socio-demographic and clinical data were recorded. Blood samples were drawn for HIV and HBV diagnosis. All categorical variables were summarized into frequencies. Results There were 185/325 (56.9 %) females. The mean age (SD) was 23.0 ± 7.5 years. The prevalence of HIV was 1.8 %; the prevalence of HBV was 1.2 %. Conclusions The prevalence of both HIV and HBV in SCD patients is no greater than in the general population of Dar es Salaam or Tanzania. For associations, a large study would be needed. From a detailed blood transfusion history of SCD patients we found no evidence that HIV or HBV infection was transmitted through blood transfusion.


The Lancet ◽  
1982 ◽  
Vol 320 (8310) ◽  
pp. 1286
Author(s):  
M.S. Al Adnani ◽  
F.M. Al Kasab ◽  
F.A. Al Alusi

Sign in / Sign up

Export Citation Format

Share Document